Abstract
Provided herein are bispecific molecules and methods of treating using the bispecific molecules, wherein the bispecific molecules comprise a first binding domain and a second binding domain, wherein the first binding domain binds TL1A, a variant thereof or a functional fragment thereof, and wherein the second binding domain binds any one of IL-6R, IL-6, IL-12, IL-23, an IL-17 family cytokine, IL-17R, a variant thereof, and a functional fragment thereof.
Full Text
What is claimed is:
Provided herein are bispecific molecules and methods of treating using the bispecific molecules, wherein the bispecific molecules comprise a first binding domain and a second binding domain, wherein the first binding domain binds TL1A, a variant thereof or a functional fragment thereof, and wherein the second binding domain binds any one of IL-6R, IL-6, IL-12, IL-23, an IL-17 family cytokine, IL-17R, a variant thereof, and a functional fragment thereof.
Timeline
Filed
05/22/2026Published
09/10/2026Granted
Not AvailableIPC Codes(3)
C07K 16/28:against receptors, cell surface antigens or cell surface determinants
C07K 16/24:against cytokines, lymphokines or interferons
C07K 16/46:Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K 19/00)